HCA Red Flag: Genmab earns more than expected, but leaves guidance untouched (AI)
HC Andersen Capital
Summary
- Genmab's Q3 2026 operating profit was USD 452M, exceeding expectations of USD 379M, but the company maintained its full-year guidance at USD 1,225M, below the expected USD 1,273M.
- Despite a 92% increase in share price over three months, Genmab did not revise its guidance upward, indicating potential cost increases in Q4 to meet the annual cost framework of USD 2.88B.
- Net income for the quarter was USD 342M, significantly higher than the expected USD 224M, aided by a low tax rate and reduced costs, though the tax benefit from the Merus acquisition is temporary.
- Operating cash flow improved to USD 520M in Q3 from USD 54M in H1, alleviating pressure from the USD 5.0B debt incurred for the Merus acquisition.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Automatic translation: Originally published in Danish 05/11/2026, 16:15 GMT. Give feedback here.
| Red Flag · First reading of the financial report · AI-generated content HCA Red Flag: Genmab earns more than expected, but leaves guidance untouched (AI) Genmab (GMAB) · Q3 2026 · November 5 Share +92% in three months, 7% below the record price |
Overall assessment: Slightly negative assessment
| Positive view | Balanced | Negative view |
Genmab is maintaining the midpoint of USD 1,225M for this year's adj. operating profit vs. the expected USD 1,273M, which, following a 92% share price increase, points to a slightly lower opening. The quarter's USD 452M vs. the expected USD 379M will only lift estimates if fourth-quarter costs are kept down.
Red flags in the financial statement
Genmab does not raise guidance despite the quarter's profit
Unchanged: USD 1,225M · Est. USD 1,273M
The midpoint for this year's adj. operating profit (earnings before interest and taxes) remains unchanged, below analysts' expectations. Following a 92% share price increase over three months, the share needed an upward revision, which failed to materialize.
Guidance requires 52% higher costs in the fourth quarter
Implicit Q4: USD 984M · Q3: USD 647M
Genmab spent less on research and sales than expected, but maintains this year's cost framework of USD 2.88B. If the framework holds, the quarter's profit is due to deferred costs rather than a permanent saving.
Epkinly grew only 2% from the second quarter
Q3: USD 179M · Q2: USD 175M
Genmab's own lymphoma drug Epkinly slowed down after 28% growth from the first to the second quarter. Over the long term, proprietary drugs are expected to replace royalties from the cancer drug Darzalex.
Green flags in the financial statement
Operating profit was 19% higher than expected
Actual USD 452M · Est. USD 379M
Total operating expenses came in at USD 668M vs. the expected USD 750M, while revenue hit the expected USD 1.19B. If the lower level holds, full-year earnings estimates will need to be raised.
Net income was one and a half times larger than expected
Actual USD 342M · Est. USD 224M
A tax rate of only 3.4% and lower costs boosted net income. The tax benefit from the acquisition of Merus is temporary, meaning only the cost component can move estimates for the coming years.
Operating cash flow has turned around
Q3: USD 520M · H1: USD 54M
Operations generated significantly more cash in the third quarter following a weak first half. This eases the pressure from the USD 5.0B debt that Genmab took on to acquire Merus.
Disclaimer: This is an HCA AI-generated research commentary based solely on the company's published financial statement. The commentary does not constitute investment consulting and should not be used as the sole basis for investment decisions. Investing in shares involves the risk of loss. Seek professional consulting. /HC Andersen Capital, 17:13, 11/5/2026